T here is overwhelming evidence from studies that antihyperlipidaemic drugs are effective in coronary heart disease (CHD) prevention, even though there are many controversies associated with their use. This evidence, although not based on prospective outcomes research under real-life budgetary conditions, has led to the development of treatment guidelines for the prevention of CHD. At the inaugural European conference of the International Society for Pharmacoeconomics and Outcomes Research [ Cologne, Germany; December 1998 ], Dr Karl Lauterbach from the University of Cologne, Germany, outlined a prospective study that aims to help sickness funds decide, under realistic conditions, who should receive statin therapy. Meanwhile, even though evidence-based CHD prevention guidelines are available, the potential for preventive CHD care is not being fully realised by physicians and patients in everyday clinical practice, according to the results of the EUROASPIRE* study.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
* European Union Action on Secondary Prevention through Intervention to Reduce Events
About this article
Cite this article
Todd, C. Using evidence-based medicine to deliver cost-effective care in CHD. Pharmacoecon. Outcomes News 200, 3–5 (1999). https://doi.org/10.1007/BF03294994
- Coronary Heart Disease
- Statin Therapy
- Nicotine Replacement Therapy
- Coronary Heart Disease Risk